Arie ©®™ (@satyavacas.bsky.social)

FDA Approves Icotrokinra, First Oral IL-23 Inhibitor for Plaque Psoriasis The U.S. Food and Drug Administration (FDA) has approved ICOTYDE (icotrokinra), a first-in-class oral targeted peptide for adults and pediatric patients aged 12 years and older with moderate-to-severe https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide